I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $371.25M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
| | ||||
Acadia Pharmaceuticals Inc. |
San Diego, Calif. |
3/28 |
$25 |
Acadia raised $25M in a private financing led by Oxford Bioscience Partners; other investors were OrbiMed Advisors LLC, Federated Kaufmann Fund, LD Pensions, Hambrecht & Quist Capital Management LLC, ABN AMRO Ventures, Carnegie Fund II Biotechbridge and Dansk Kapitalanlaeg Aktieselskab |
|
||||
Agensys Inc. |
Santa Monica, Calif. |
3/5 |
-- |
Agensys secured a $3M line of credit from Silicon Valley Bank |
|
||||
Cellzome AG |
Munich, Germany |
3/25 |
€30 |
Cellzome raised US$32.23M in its third round led by Invesco Private Capital, Biofrontier Partners, SG Asset Management and Yamanouchi Venture Capital; other investors were Atlas Ventures, Advent International, Index Ventures, Heidelberg Innovation, Schroder Ventures Life Sciences, Sofinnova Partners and Stelios Papadopoulos |
|
||||
Chiasma |
Netanya, Israel |
3/25 |
$2 |
Chiasma received $2M in seed financing from InnoMed |
|
|
|||
Corus Pharma |
Seattle, Wash. |
3/7 |
$40 |
Corus raised $40M in a Series B preferred stock offering led by JPMorgan Partners, RBC Capital Partners and Novo Nordisk A/S; other investors were Burrill & Co., OrbiMed Advisors,Cascade Investment, Washington Research Foundation, Anthem Venture Partners, MDS Capital and Integra Ventures |
|
|
|||
FRIZ Biochem GmbH |
Munich, Germany |
3/28 |
€3 |
FRIZ raised US$3.26M in the first tranche of a Series B financing led by Global Life Science Ventures; other investors were DRF Beteiligungsgesellschaft |
|
|
|||
GenVault Corp. |
Carlsbad, Calif. |
3/24 |
$10 |
GenVault raised $10M in a Series A round from funds managed by Domain Associates LLC |
|
||||
Hypnion Inc. |
Worcester, Mass. |
3/17 |
$47.5 |
Hypnion raised $47.5M in a Series B round co-led by Forward Ventures and MPM Capital; other investors were Advanced Technology Ventures, S.R. One Ltd., Jafco Co. Ltd., Coastview Capital, Oxford Bioscience Partners, Flagship Ventures and GIMV Venture Capital |
|
||||
Iomai Corp. |
Gaithersburg, Md. |
3/31 |
$2 |
Iomai raised an additional $2M in its Series C, bringing the total for the round to $56M; the $2M was provided by AIG Global Investment Corp. |
|
||||
OncoGenome |
Liege, Belgium |
3/12 |
€14 |
OncoGenome raised US$15.43M in a financing co-led by funds advised by PolyTechnos Venture-Partners and Life Sciences Partners; other investors were Technowal SA, Meusinvest and S.I.B.L. |
|
|
|||
Peptimmune Inc. |
Cambridge, Mass. |
3/11 |
$41.2 |
Peptimmune raised $41.2M in its first round, co-led by New Enterprise Associates and MPM Capital; other investors were Prism Venture Partners, Vanguard Ventures, Hunt Ventures LP and Boston Medical Investors Inc. |
|
||||
Sopherion |
New Haven, Conn. |
3/7 |
$26 |
Sopherion raised $26M in its first round led by TL Ventures; other investors were HealthCap KB, ProQuest Investments, Johnson & Johnson Development Corp., Intersouth Partners, Seaflower Ventures, Connecticut Innovations Inc. and GE Life Science and Technology Finance |
|
||||
StemCo |
Research Triangle Park, N.C. |
3/18 |
$9.8 |
StemCo raised $9.8M in a Series B round led by Intersouth Partners and The Aurora Funds; other investors were Becton Dickinson Ventures, The Trelys Funds LP, Tall Oaks Capital Partners and unnamed individuals |
Synta Pharmaceuticals Inc. |
Lexington, Mass. |
3/28 |
$75.3 |
Synta raised $75.3M in a Series B round; investors were Keith Gollust, Bruce Kovner, Robert Day, Stanley Druckenmiller, the Wolfensohn Family Foundation and various other undisclosed management consulting and financial institution partners |
|
||||
Targacept Inc. |
Winston-Salem, N.C. |
3/19 |
$14 |
Targacept raised another $14M in its second round, bringing the total raised to $60M; investors were Oxford Bioscience Partners, Jafco Co. Ltd., Cogene Biotech Ventures, Bison Capital and Rock Castle Ventures |
|
||||
UroGene SA |
Genopole, France |
3/19** |
€12 |
UroGene raised US$12.68M in a round led by SGAM; other investors that participated were GenAvent and Capricorn Venture Partners |
|
|
|
||
Zealand |
Glostrup, Denmark |
3/27 |
€5 |
Zealand raised US$5.45M in a financing led by |
|
|
|
||
Zelos |
Waltham, Mass. |
3/24 |
C$14 |
Zelos raised US$9.4M in a first round led by Seaflower Ventures and VenGrowth Capital Partners Inc.; Genesys Capital Partners also participated |
|
|
|||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $74M | ||||
Company |
Partner |
Amt. |
Triggering Event |
Details (Date) |
| | ||||
Access Pharmaceuticals |
Fujisawa Pharmaceutical Co. Ltd. (Japan) |
ND |
Milestone |
Access received a payment following marketing approval in France for Zindaclin (3/13) |
|
||||
Aderis Pharmaceuticals* |
Fujisawa Healthcare Inc. |
$2 |
Milestone payment |
Aderis received a $2M payment in connection with the final report from a Phase II study of DTI-0009, which is being developed to control heart rate during atrial fibrillation (3/19) |
|
||||
ArQule Inc. |
Pfizer Inc. |
$5 |
Equity investment |
ArQule received the $5M investment for achieving its 2002 collaboration goals (3/18) |
|
|
|
||
Avigen Inc. |
Bayer AG |
$2.5 |
Milestone |
Avigen received the payment as part of an option agreement to support the hepatic route of administration for Coagulin-B (3/3) |
|
|
|
||
Enanta |
Chiron Corp. |
ND |
Milestone |
Enanta received the payment after completing the first phase of research for the discovery and development of small-molecule therapeutics for the hepatitis C virus (3/12) |
|
|
|
||
Gamida-Cell |
Teva |
$3 |
Investment |
Teva invested $3M in Gamida-Cell, which developed a technology designed to expand the population of stem cells with minimal differentiation (3/12) |
|
|
|
||
ImClone |
Bristol-Myers |
$60 |
Milestone |
ImClone received the $60M payment for reaching the one-year anniversary of the signing of the companies' amended agreement for Erbitux (3/6) |
|
|
|
|
|
Kosan Biosciences Inc. (KOSN) |
Johnson & Johnson Pharmaceutical Research & Development LLC (unit of Johnson & Johnson) |
ND |
Milestone payment |
Kosan received a payment after J&J identified a Kosan-generated macrolide antibiotic that meets the preclinical criteria of a new chemical entity specified under their collaboration (3/26) |
|
|
|||
Ligand Pharmaceuticals Inc. (LGND) |
Eli Lilly and Co. |
$1.5 |
Milestone payment |
Ligand received a $1.5M milestone payment from Lilly, which advanced into Phase II trials LY818 for Type II diabetes and metabolic diseases (3/21) |
|
|
|
||
Metabolex Inc.* |
Yamanouchi Pharmaceutical Co. Ltd. (Japan) |
ND |
Milestone payment |
Metabolex received the milestone payment when Yamanouchi selected three targets for screening as part of their collaboration (3/18) |
|
|
|
||
Syn X Pharma Inc.* (Canada) |
Ortho-Clinical Diagnostics Inc. (unit of Johnson & Johnson) |
ND |
Milestone payment |
Syn X received the payment as part of its agreement with Ortho-Clinical for Alzheimer's disease technology for human in vitro diagnostic applications (3/4) |
|
|
|
|
|
|
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed; AMEX = American Stock Exchange | ||||
